Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 391-401, June 2009

Adverse effects of therapy for ANCA-associated vasculitis

  • Jennifer Turnbull, MSci (Hons), MBChB (Hons), Doctor
    • ,
  • Lorraine Harper, PhD, MRCP, Doctor

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 121 414 7042; Fax: +44 121 627 2527.

Renal Immunobiology, Division of Immunity and Infection, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

The introduction of cyclophosphamide- and prednisolone-based treatment regimens has significantly improved outcome in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis. However, these regimens are nonspecific immunosuppressants associated with significant toxicity, including increased risk of infection, leucopenia, diabetes and malignancy. In addition, disease damage, particularly renal failure, increases the risk of toxicity. Improvements in disease management should include the increased awareness of treatment-related toxicity and its prevention.

Keywords: adverse events, ANCA-associated vasculitis, infection, immunosuppression, toxicity

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(09)00043-6

doi:10.1016/j.berh.2009.04.002

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 3 , Pages 391-401, June 2009

Article Tools